Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Alector

    Client Virtual Booth

    ALECTOR

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Alector
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    151 Oyster Point Blvd, Suite 300 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alector.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alector
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Alector to Participate in Upcoming Healthcare Conferences
    Alector to Participate in Upcoming Healthcare Conferences

    https://investors.alector.com/news-releases/news-release-details/alector-participate-upcoming-healthcare-conferences-3

    PRESS RELEASE
    28 Feb 2024
    Share Share
    Alector Reports Fourth Quarter and Full Year 2023 Financial Results
    Alector Reports Fourth Quarter and Full Year 2023 Financial Results

    https://investors.alector.com/news-releases/news-release-details/alector-reports-fourth-quarter-and-full-year-2023-financial

    PRESS RELEASE
    27 Feb 2024
    Share Share
    Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
    Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

    https://investors.alector.com/news-releases/news-release-details/alector-host-fourth-quarter-and-full-year-2023-earnings-call

    PRESS RELEASE
    20 Feb 2024
    Share Share
    Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
    Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

    https://investors.alector.com/news-releases/news-release-details/alector-announces-first-patient-dosed-progress-ad-phase-2

    PRESS RELEASE
    08 Feb 2024
    Share Share
    FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
    FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

    https://investors.alector.com/news-releases/news-release-details/fda-grants-latozinemab-breakthrough-therapy-designation

    PRESS RELEASE
    07 Feb 2024
    Share Share
    Alector Announces Closing of Public Offering
    Alector Announces Closing of Public Offering

    https://investors.alector.com/news-releases/news-release-details/alector-announces-closing-public-offering

    PRESS RELEASE
    19 Jan 2024
    Share Share
    Alector Announces Pricing of Public Offering of Common Stock
    Alector Announces Pricing of Public Offering of Common Stock

    https://investors.alector.com/news-releases/news-release-details/alector-announces-pricing-public-offering-common-stock

    PRESS RELEASE
    17 Jan 2024
    Share Share
    Alector Announces Proposed Public Offering of Common Stock
    Alector Announces Proposed Public Offering of Common Stock

    https://investors.alector.com/news-releases/news-release-details/alector-announces-proposed-public-offering-common-stock-0

    PRESS RELEASE
    16 Jan 2024
    Share Share
    Alector Reports Second Quarter 2023 Financial Results & Provides Business Update
    Alector Reports Second Quarter 2023 Financial Results & Provides Business Update

    https://investors.alector.com/news-releases/news-release-details/alector-reports-second-quarter-2023-financial-results-and

    PRESS RELEASE
    03 Aug 2023
    Share Share
    Here's Why We're Not Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
    Here's Why We're Not Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

    https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alec/alector/news/heres-why-were-not-too-worried-about-alectors-nasdaqalec-cas

    SIMPLY WALL
    27 Jun 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search